# Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

> **NCT02248805** · PHASE1 · COMPLETED · sponsor: **MacroGenics** · enrollment: 95 (actual)

## Conditions studied

- Colorectal Carcinoma

## Interventions

- **DRUG:** MGD007

## Key facts

- **NCT ID:** NCT02248805
- **Lead sponsor:** MacroGenics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2018-07-02
- **Final completion:** 2018-07-02
- **Target enrollment:** 95 (ACTUAL)
- **Last updated:** 2022-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02248805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02248805, "Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02248805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*